



中国证券监督管理委员会  
CHINA SECURITIES REGULATORY COMMISSION

维护市场公开、公平、公正

维护投资者特别是中小投资者合法权益

促进资本市场健康发展

首页  
HOME

政务

Information Policies  
disclosure and Press  
regulations Releases  
Information Statistical Personnel  
Disclosure data recruitment

服务

handling Online Regulatory  
guideline declaration target  
Business Personnel Investor  
qualification qualification protection

互动

Public Letters and Report  
message visits column column  
Online solicit Integrity  
interview opinions Review

Your location: Home > News > SFC News

## China Securities Regulatory Commission informed Kangmei Pharmaceutical's investigation progress

China Securities Regulatory Commission www.csrc.gov.cn Time: 2019-05-17 Source: China Securities Regulatory Commission

At the end of 2018, the daily supervision of the Securities Regulatory Commission found that Kangmei Pharmaceutical Co., Ltd. (Kangmei Pharmaceutical) had doubts about the authenticity of its financial report and suspected false statements and other violations of laws and regulations. I will immediately investigate the case. On December 29, Kangmei Pharmaceutical disclosed relevant information. It has been preliminarily found that the 2016-2018 financial report disclosed by Kangmei Pharmaceutical Co., Ltd. contains major falsehoods and is suspected of violating Article 63 of the Securities Law and other relevant regulations. One is to use fake bank documents to increase deposits, the other is to falsify income by forging business vouchers, and the third is to transfer part of the funds into related party accounts to buy and sell the company's stock. Recently, the Association has investigated the suspected failure of the Zhujiang Certified Public Accountants, the company's auditing agency, to commit investigations. I will announce the progress of the case to the society in a timely manner.